Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. - Wikidata - wikimedia - TriplyDB

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

http://www.wikidata.org/entity/Q44616594

about

Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development Early alterations of brain cellular energy homeostasis in Huntington disease models Creatine for treating muscle disorders Creatine for treating muscle disorders Therapeutic interventions for disease progression in Huntington's disease Creatine for treating muscle disorders Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis Skill execution and sleep deprivation: effects of acute caffeine or creatine supplementation - a randomized placebo-controlled trial.The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review Cardiac dysfunction in the R6/2 mouse model of Huntington's disease Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Development of novel therapies for Huntington's disease: hope and challenge.Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin.Emerging chemotherapeutic strategies for Huntington's disease.Therapeutics development for triplet repeat expansion diseases.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.The application of NMR-based metabonomics in neurological disorders.Emerging drugs for Parkinson's disease.Huntington's disease: pathological mechanisms and therapeutic strategies.Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body Huntington's disease: progress and potential in the field.Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.Role of creatine supplementation on exercise-induced cardiovascular function and oxidative stress.Exploring the therapeutic role of creatine supplementation.Mitochondria: a therapeutic target in neurodegeneration Emerging drug therapies in Huntington's disease.Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.Energy deficit in Huntington disease: why it matters.Creatine in mouse models of neurodegeneration and aging.Pharmacologic approaches to the treatment of Huntington's disease.Protein oxidation in Huntington disease.Neuroprotective effects of psychotropic drugs in Huntington's disease A mitochondrial basis for Huntington's disease: therapeutic prospects.Investigational drugs for the management of Huntington's disease: are we there yet?Animal models of Huntington's disease for translation to the clinic: best practices.

P2860

Q22241837-E935A8EC-FD7D-46BF-85DA-C6145707A71A Q23912810-5C4A3F5E-D358-4CB9-A5D4-4A7BE0B72899 Q24202243-8B98E08B-D970-465B-802D-04A83EACA7DB Q24236598-8E706A14-EF35-4FD7-B2E8-138B0225301C Q24239973-2C89B7C3-6F96-4053-BFEE-496FAAE317B7 Q24246414-6FA235D6-AF87-4760-AC30-B4DE239F2161 Q27338799-BF97941D-51DB-49CD-A4FE-B30970C435BD Q33791877-E826DE23-D9A3-406C-B274-39CF260321DE Q33837238-FC0692A1-3238-4536-ADAD-A0603101981B Q34610044-6B5A1F06-D159-4F4D-A40A-694AE87A85EF Q34626123-3A6ED8B1-EFD2-46D2-B6D4-5FABA66D8B10 Q35597607-2C14F3A1-7A4D-41D2-8425-2B1B8D5D8553 Q35745626-193EC908-647F-4C63-8DFB-380B13BE6599 Q35940409-5E6DF976-4A9A-40A4-985D-FFAAF07391DC Q35958359-2FC94C65-B37F-4F38-9A21-45983980A288 Q36016932-7773EB44-E93C-4534-88F0-882B6147F6D7 Q36080317-A82A92BC-CB68-4353-9549-8397CAE61E49 Q36150628-FB95B8E9-CC54-4F4A-8BB2-2B258A48BA5F Q36277195-7F70B341-C63D-4783-99C8-B3EB327FD29A Q36358871-C9C01D0C-0717-46EE-B1E6-8C969AB384DA Q36525175-1A873937-2B4B-42FA-9751-BBA45D0791E1 Q36580572-F6B4E2EE-02C0-4662-8B46-249E13A8470E Q36822322-EE8CA0EF-218E-48C3-AAB2-67E836288889 Q36999830-427A9914-B8E0-4E3B-BBF0-C08E9B60E8EA Q37016096-D4943A2D-175E-4099-BDB4-4165D538A4CB Q37348546-2F59EC01-C08F-4B8B-B4BF-F21D732C9C9D Q37390314-EFA8208E-BA5B-41B8-B42D-F7EEB44A04F4 Q37404612-FE136C07-BB7D-4785-8CD4-DD8C48BBB2A2 Q37466059-4B124D7C-476C-4E2F-A847-E0A802ACFFBA Q37488273-60647FB6-5FDE-4D55-BEF4-B54C54D49D02 Q37580731-955983FA-C4A0-4803-890C-14D41A71F070 Q37698597-7A63A7C5-DE54-494C-81CF-3A2D395333DA Q37834195-E4D5E05A-871D-4873-AF09-101D72766A41 Q37851389-1FD91C1B-F449-4925-8D90-C3F0D2E9C458 Q37945478-0C3A9FD2-10BF-4795-93BE-826FBF26A157 Q37999718-96210C65-4F76-47BC-8656-F6822796D506 Q38163877-ADCD0179-14A2-42F2-881A-1941A05DEF0F Q38174451-E8BFA65D-01DE-49BC-BCA6-D91058DBDC76 Q38236052-D2FF64D6-0D6F-424D-97BA-1A6469264816 Q38248687-E421F150-E34D-41AF-9750-E120578C7229

P2860

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

http://www.wikidata.org/entity/Q44616594

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@en

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@nl

type

label

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@en

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@nl

prefLabel

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@en

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@nl

P1433

Q44616594-2C62AC43-3C9D-43BD-BD08-598725B7E309

P1476

Q44616594-CFD49971-2327-418F-A564-C078C7F4C03D

P2093

Q44616594-0A9A886E-9270-4AAE-B26A-3C1A73399943

Q44616594-513BB3E6-C37B-47E3-B3F0-174EF6864AA4

Q44616594-5B6FDC64-EDC2-499F-999D-50F5EB0445BC

Q44616594-7907AA49-60A9-40F4-8007-F7AC72888EF1

Q44616594-B79C214F-4AAE-4D0A-A532-219D20FCCE37

Q44616594-C1C18597-263B-4F6F-B680-080F65F14D0B

Q44616594-F178B246-8C0B-4F74-A3CE-06247A4A29FB

Q44616594-F71E5B72-E48E-450A-8025-4B7C9083A8DD

P304

Q44616594-CA4FB8A9-93DF-4425-9462-5338C7FD45B5

P31

Q44616594-DAD98A0C-E271-420D-BD43-0127771C7A4A

P356

Q44616594-69E8E2FE-8390-416F-8DC0-DCE429315B36

P407

Q44616594-B29D9EC1-9A9D-4C9A-8640-9A82965B895F

P433

Q44616594-B2013F76-34FE-42E4-A79A-2FF9B842C55D

P478

Q44616594-6EBF6AF1-FBBD-4CE7-BD8E-FEDC32462801

P577

Q44616594-147F7B03-FD15-48B7-A1AE-97796D1282EB

P698

Q44616594-4169BF7E-330B-484F-8806-D03F531C43B8

P921

Q44616594-1F60A048-C5CB-4E44-AE7F-BEA68B7B963B

Q44616594-649808C0-0E67-45DC-83AC-8E79FA46A2F7

P356

01.WNL.0000090629.40891.4B

P1433

P1476

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.

@en

P2093

Dom R

http://www.w3.org/2001/XMLSchema#string

Eijnde BO

http://www.w3.org/2001/XMLSchema#string

Hespel P

http://www.w3.org/2001/XMLSchema#string

Lemiere J

http://www.w3.org/2001/XMLSchema#string

Swinnen S

http://www.w3.org/2001/XMLSchema#string

Van Leemputte M

http://www.w3.org/2001/XMLSchema#string

Vanhees L

http://www.w3.org/2001/XMLSchema#string

Verbessem P

http://www.w3.org/2001/XMLSchema#string

P304

925-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000090629.40891.4B

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14557561

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease